Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type6 |2 ~+ X/ H3 @( E" _; R
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
) C6 r6 E* h2 J9 A# l+ `+ Author Affiliations# e% C7 L: x- i q: V% Q c
% o2 M0 n- l8 q# P, B& o0 H c0 \1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
( g$ h1 T) O+ S8 ~, ~ H; f7 ?9 F2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ; L1 d+ u/ Q8 ]; v
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
) ~& @* r# N; ?, A$ R# N$ n* P( w4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
0 E# i/ ]8 W- H- x5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan ! A3 y: G1 w. O" a7 |0 A3 J
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
- g* p* c: M V5 ]5 F7Kinki University School of Medicine, Osaka 589-8511, Japan
- e& q- e# o# K1 f- o8Izumi Municipal Hospital, Osaka 594-0071, Japan 7 y1 b; w4 v1 u4 i
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
% a5 Z3 H9 k0 b! b# h1 m% OCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp & ?- ^& Y$ n1 o
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. # ^% b4 O C" h$ \- a4 U
" X" w1 t" f! _* t) D. m0 n! L5 P* O$ X
|